You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.9% | 4.5% |
| Div Cover | n/a | 2.6 |
| Op Mrgn | n/a | 27.1% |
| ROCE | n/a |
| Latest | Forecast | |
|---|---|---|
| P/E | 39.6 | 0.0 |
| PEG | -0.5 | -49.7 |
| Price / Revenue | 9.6 | 1.8 |
| Price / Book value | 5.3 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 3.4% | 0.0% |
| PBT | 7.7% | n/a |
| EPS | 11.0% | 0.0% |
| DPS | -4.5% | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
| 2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -1.0 | -22% | 80.00p | 4.0% |
| 2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.2 | 54% | 44.00p | 3.1% |
| 2023-12-31 | 30,328.00 | 6,064.00 | 155.10p | 9.4 | 2.8 | 3% | 42.00p | 2.9% |
| GSK reports positive results from ovarian cancer drug trial Sharecast News | 20 Dec |
|---|---|
| EU recommends expanding use of GSK endometrial cancer drug Sharecast News | 16 Dec |
| GSK says US agrees to look at data for new use of COPD drug Sharecast News | 09 Dec |
| Director/PDMR Shareholding | 23-Dec-24 15:30 |
|---|---|
| Block Listing Application | 20-Dec-24 09:00 |
| Headline results from phase III FIRST trial | 20-Dec-24 07:01 |
| Jemperli receives US FDA breakthrough designation | 16-Dec-24 07:12 |
| EMA grants PRIME Designation for GSK’227 | 16-Dec-24 07:05 |